BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 7, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy,

Open original release

Related news

PLSEPulse Biosciences2026-04-25 17:00 EST

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

PLSEPulse Biosciences2026-03-17 11:00 EST

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

DCTHDelcath Systems2026-04-06 12:30 EST

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

AEMDAethlon Medical2026-07-13 12:01 EST

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

HYPRHyperfine2026-04-29 12:15 EST

Hyperfine Swoop® System Introduced as India’s First Portable MRI for Bedside Brain Imaging at the Country’s Leading Medical Institution

SGHTSight Sciences2026-04-01 20:05 EST

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

TCMDTactile Systems Technology, Inc.2026-07-13 12:00 EST

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

ADPTAdaptive Biotechnologies2026-05-29 11:30 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

HYPRHyperfine2026-04-09 12:15 EST

Hyperfine Receives CE and UKCA Marks for Next-Generation Swoop® System and Latest Advancement in Optive AI™ Software

View all latest news

Pulse Biosciences

Pulse Biosciences is a medical technology company focused on nano-pulse stimulation and nonthermal cellular treatments. Its platform is intended to create new ways to treat tissue while preserving surrounding structures.

Recent company news

PLSEPulse Biosciences2026-05-27 20:05 EST

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

PLSEPulse Biosciences2026-05-12 11:00 EST

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

PLSEPulse Biosciences2026-05-08 11:00 EST

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

PLSEPulse Biosciences2026-05-04 11:00 EST

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

PLSEPulse Biosciences2026-04-25 17:00 EST

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Stock data

Close
32.79 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States